Alembic Pharmaceuticals valuation

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
Price multiples — at each FY-end close
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
22.61×————
2.75×————
2.01×————
44.88×————
Enterprise multiples
2.16×————
14.36×————
20.30×————
Yield
4.4%————
2.2%————
Reference — adjusted share basis
₹794.85————
₹35.16₹34.33₹29.68₹31.33₹17.40
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

APLLTD₹794.85

Alembic Pharmaceuticals Ltd.

· Pharma & Health
₹ CrorePeersAJANTPHARMIPCALABTORNTPHARMALIVUSAKUMSAGARWALEYEADVENZYMESAARTIPHARMMcap ₹15,623 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
Multiples — ₹ Crore base
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Price Multiples — at each FY-end close
P/E————22.61
P/B————2.75
P/Sales————2.01
Price to Free Cash Flow————44.88
Enterprise Multiples
EV/Sales————2.16
EV/EBITDA————14.36
EV/EBIT————20.30
Yield
Earnings Yield %————4.42
FCF Yield %————2.23
Reference — adjusted share basis
Price (FY-end close, adj.)————794.85
EPS (adj.)17.4031.3329.6834.3335.16
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.